Public, crawlable companion record for the descriptive tolerability summary covering study completers who had prior experience with Latisse. Key findings, limitations, and the complete formatted PDF are available below.
- Study completers
- 85
- Prior Latisse users
- 30
- Reported prior Latisse side effects
- 24 of 30
- Adverse effects reported during Plume use
- 0 of 85
What was reported
Among the 30 study completers with prior Latisse experience, 24 participants, or 80%, self-reported having experienced adverse side effects during their earlier Latisse use. No adverse effects were reported among the full group of 85 completers during eight weeks of Plume Elite use.
Participants remained under the routine oversight of their own healthcare providers, including general practitioners, optometrists, dermatologists, and ophthalmologists, as applicable.
Formula and claim context
Plume Elite Prostaglandin-Free Lash & Brow Serum is formulated without prostaglandin analogs. The phrase Zero Prostaglandin Side Effects refers specifically to effects associated with prostaglandin-analogue exposure. Individual tolerability varies, and these aggregate findings do not guarantee that every user will be free from irritation or sensitivity.
Access the source documents
Source: Plume Science study records and participant self-report. This was a company-sponsored descriptive product-use study. Latisse is a trademark of its respective owner; Plume Science is not affiliated with or endorsed by that owner.
Questions and scope
Was this a head-to-head efficacy study against Latisse?
No. The comparison was limited to descriptive tolerability history and did not evaluate comparative efficacy, speed, lash growth, or causation.
What does the 80 percent prior-Latisse figure mean?
Twenty-four of the 30 study completers with prior Latisse experience self-reported having experienced adverse side effects during their earlier Latisse use.
Does zero adverse effects guarantee that Plume Elite cannot irritate anyone?
No. No adverse effects were reported among the 85 completers during the eight-week observation period, but individual tolerability varies.